DRL 11605

Drug Profile

DRL 11605

Alternative Names: DRF 11605; DRL-11605

Latest Information Update: 26 May 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dr Reddys Laboratories; Perlecan Pharma
  • Developer Perlecan Pharma
  • Class Antihyperglycaemics; Antihyperlipidaemics; Obesity therapies
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Lipid metabolism disorders; Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 26 May 2009 Discontinued - Phase-I for Obesity in Canada (unspecified route)
  • 21 Mar 2007 Discontinued - Preclinical for Lipid metabolism disorders in India (unspecified route)
  • 21 Mar 2007 Discontinued - Preclinical for Type-2 diabetes mellitus in India (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top